Vertex casually drops Orkambi revenue slowdown, creating

Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about | Cystic fibrosis drugmaker Vertex this week informally backed away from its revenue guidance for key med Orkambi--and investors should be just as unhappy with execs’ conduct as they should be about the revenue slip, one analyst says.

Lawrence Journal-World 06-18-2016 by Lawrence Journal-World - Issuu

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

October, 2015

Vertex casually drops Orkambi revenue slowdown, creating 'unnecessary drama' for investors

SEC Filing – Royalty Pharma

SEC Filing – Royalty Pharma

Vertex Pharmaceuticals' Revenue by Product (2016-2023)

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

SEC Filing – Royalty Pharma

Vertex (VRTX) Beats on Q4 Earnings & Sales, '23 View Encouraging

Amendment No. 1 to Draft Registration Statement